GLP1 Guide (Page 2)

Mexico and GLP1s

We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.

Shortages threaten corporate profits, likely to end soon

We think the GLP1 shortage is going to end in the first half of 2025. Here's why.

Ozempic approved for Chronic Kidney Disease

The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.

Tradjenta: An alternative to GLP1 for Type 2 Diabetes

We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.

GLP1 use by younger people

We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.

Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

The battle for compounded GLP1 continues

The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.

Government Price negotiations on Ozempic and Wegovy

The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?

Pancreatitis and Gallstones after massive weight loss

We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s

What's the best injection site for GLP1s?

What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.

Zepbound coverage for Sleep Apnea gets Agency approval

Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.

Robert F. Kennedy Jr vs GLP1

RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?

research

Research suggesting GLP1 is a brain drug

Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.

usecase:kidney-disease

Tirzepatide's benefits extend to Kidney Disease

Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.

company:hikma

Another Generic Liraglutide launch: Hikma Phamaceuticals

A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.

category:news

HIMS to offer Liraglutide after shortage rule changes

HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?

chemical:lixisenatide

Adlyxin's 2025 Patent expiry

Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.

categeory:watercooler

Research models applied to GLP1s and Plateaus

New research that shows a benefit to appetite feedback control circuits via mathematical modeling, showing the benefits of using GLP1s.

22.7% weight loss yet Novo Nordisk stock drops 27%

Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.

chemical:semaglutide

Semaglutide & Liraglutide continue to be effective

Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.

category:watercooler

Lizzo's as a lens on GLP1 public opinion

We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.

company:eli-lilly

Eli Lilly brands GLP1s as "anti-hedonics"

Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"